Global Epidemiology of Drug-Induced Liver Injury (DILI)

AbstractPurpose of ReviewDrug-induced liver injury (DILI) is not an uncommon liver disease in many parts of the world. DILI is one of the most common causes of acute liver failure in most countries. The current review summarizes the global epidemiology of DILI.Recent FindingsThe number need to harm in terms of DILI due to amoxicillin-clavulanate was approximately 1 out 2300, but was higher for azathioprine (1 out of 133) and infliximab (1 out of 148). A retrospective Chinese study showed the highest rate of DILI in hospitalized patients with an incidence of approximately 24 patients per 100,000 annually with a more favorable prognosis in the DILI cohort than previously reported from Europe, the USA, and Asia.SummaryAlthough large DILI registries from Europe and the USA have collected much data, more prospective studies with continual enrollment are needed particularly as new therapies such as immune modulatory and oncological medications with longer half-lives and latencies come to market.
Source: Current Hepatitis Reports - Category: Infectious Diseases Source Type: research